Article

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients With Migraine: 3 Cases

2023-01-26

Abstract excerpt

A new treatment option for cluster headache (CH) prevention is needed. Monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) ligands are used as a preventative treatment for migraine. Considering the CGRP’s role in the CH attack’s ignition and upkeep, fremanezumab and galcanezumab have been evaluated for CH preventative treatment. However, only high-dose (300 mg) galcanezumab was proven for e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 946b9f10-44a0-5bfa-89eb-9ced5af862d2
DOI: 10.20944/preprints202301.0469.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients With Migraine: 3 CasesDOI 10.20944/preprints202301.0469.v1Read

Galcanezumab Add-on in Refractory Cluster HeadacheSemantic proximity Read

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – An updated systematic review and meta-analysisSemantic proximity Read

Efficacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-AnalysisSemantic proximity Read

Predictors of galcanezumab response in a real-world study of Korean patients with migraineSemantic proximity Read

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world DataSemantic proximity Read

Cluster headache: new targets and options for treatmentSemantic proximity Read

Cgrp Monoclonal Antibodies: Key Lessons from Real World EvidenceSemantic proximity Read

Safety efficacy and tolerability of the calcitonin gene-related peptide monoclonal antibodies for migraine prevention in a real world settingSemantic proximity Read

Unveiling the Efficacy and Safety of Erenumab, a Monoclonal Antibody Targeting Calcitonin Gene-related Peptide (CGRP) Receptor, in Patients with Chronic and Episodic Migraine: A GRADE-assessed Systematic Review and Meta-analysis of Randomized Clinical Trials with Subgroup AnalysisSemantic proximity Read

Anti-calcitonin Gene-Related Peptide Monoclonal Antibody Is Effective for Preventing Migraine Aura without HeadacheSemantic proximity Read

Erenumab in highly therapy-refractory migraine patients First German Real-world evidenceSemantic proximity Read

Effectiveness and Tolerability of Anti-Calcitonin Gene-related Peptide Therapy for Migraines and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USASemantic proximity Read